Shamburg News · 8-K filed Oct 23, 2026, 5:00 PM EDT
Phathom Discloses BDR Lawsuit Against FDA Over VOQUEZNA GAIN Act Exclusivity
PHAT · Phathom Pharmaceuticals, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
Phathom Pharmaceuticals disclosed that on October 23, 2026, BDR Pharmaceuticals International filed suit against the FDA in the U.S. District Court for the District of Columbia. BDR challenges FDA's alleged refusal to receive an ANDA referencing Phathom's VOQUEZNA NDA and its application of the GAIN Act to extend NCE exclusivity. Phathom stated it believes FDA correctly recognized 10 years of NCE exclusivity through May 3, 2032 in its June 6, 2025 grant of its Citizen Petition, and that it intends to take appropriate action to protect its statutory exclusivities.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-430621.
Written from the filing by Shamburg Markets. Figures are as reported by the company.